Literature DB >> 9279180

Pulmonary function changes after nebulised and intravenous frusemide in ventilated premature infants.

V G Prabhu1, M Keszler, R Dhanireddy.   

Abstract

AIMS: To compare the effects of a single dose of frusemide administered either intravenously or by nebulisation on pulmonary mechanics in premature infants with evolving chronic lung disease.
METHODS: The effect of frusemide on pulmonary mechanics was studied at a median postnatal age of 23 (range 14-52) days in 19 premature infants at 24 to 30 weeks gestational age, who had been dependent on mechanical ventilation since birth. Frusemide (1 mg/kg/body weight) was administered, in random order, intravenously and by nebulisation, on two separate occasions 24 hours apart. Pulmonary function studies were performed before and at 30, 60, and 120 minutes after administration of frusemide. Urine was collected for six hours immediately before and for six hours after administration of frusemide.
RESULTS: Nebulised frusemide increased the tidal volume 31 (SE 11.5)% and compliance 34 (SE 12)% after two hours, whereas no change in either was noted for up to two hours after intravenous frusemide administration. Neither intravenous nor nebulised frusemide had any effect on airway resistance. Six hour urine output increased from a mean (SE) of 3.3 (0.4) ml/kg/hour to 5.9 (0.8) ml/kg/hour following intravenous frusemide administration while nebulised frusemide had no effect on urine output. Urinary sodium, potassium, and chloride losses were also significantly higher after intravenous frusemide, whereas nebulised frusemide did not increase urinary electrolyte losses.
CONCLUSION: Single dose nebulised frusemide improves pulmonary function in premature infants with evolving chronic lung disease without adverse effects on fluid and electrolyte balance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9279180      PMCID: PMC1720662          DOI: 10.1136/fn.77.1.f32

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  21 in total

1.  Inhibition of adenosine 5'-monophosphate- and methacholine-induced bronchoconstriction in asthma by inhaled frusemide.

Authors:  R Polosa; L C Lau; S T Holgate
Journal:  Eur Respir J       Date:  1990-06       Impact factor: 16.671

2.  Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia.

Authors:  M G Rush; B Engelhardt; R A Parker; T A Hazinski
Journal:  J Pediatr       Date:  1990-07       Impact factor: 4.406

3.  Evaluation of neonatal pulmonary mechanics and energetics: a two factor least mean square analysis.

Authors:  V K Bhutani; E M Sivieri; S Abbasi; T H Shaffer
Journal:  Pediatr Pulmonol       Date:  1988

Review 4.  Pharmacotherapy in bronchopulmonary dysplasia.

Authors:  P W Blanchard; T M Brown; A L Coates
Journal:  Clin Perinatol       Date:  1987-12       Impact factor: 3.430

5.  Nebulized furosemide in infants with bronchopulmonary dysplasia.

Authors:  A Rastogi; M Luayon; O A Ajayi; R S Pildes
Journal:  J Pediatr       Date:  1994-12       Impact factor: 4.406

6.  Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: results of a double-blind crossover sequential trial.

Authors:  L C Kao; D Warburton; M H Cheng; C Cedeño; A C Platzker; T G Keens
Journal:  Pediatrics       Date:  1984-07       Impact factor: 7.124

7.  Maximum diuresis--a factor in predicting recovery from respiratory distress syndrome and the development of bronchopulmonary dysplasia.

Authors:  A R Spitzer; W W Fox; M Delivoria-Papadopoulos
Journal:  J Pediatr       Date:  1981-03       Impact factor: 4.406

Review 8.  Edema formation in the newborn lung.

Authors:  R D Bland
Journal:  Clin Perinatol       Date:  1982-10       Impact factor: 3.430

9.  Bronchopulmonary dysplasia: possible relationship to pulmonary edema.

Authors:  E R Brown; A Stark; I Sosenko; E E Lawson; M E Avery
Journal:  J Pediatr       Date:  1978-06       Impact factor: 4.406

10.  Pulmonary and renal responses to furosemide in infants with stage III-IV bronchopulmonary dysplasia.

Authors:  H Patel; T F Yeh; R Jain; R Pildes
Journal:  Am J Dis Child       Date:  1985-09
View more
  10 in total

1.  Nebulized furosemide in the treatment of bronchopulmonary dysplasia in preterm infants.

Authors:  Jasmine Sahni; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

Review 2.  Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.

Authors:  Jenny K Koo; Robin Steinhorn; Anup C Katheria
Journal:  J Perinatol       Date:  2021-07-09       Impact factor: 2.521

Review 3.  Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

4.  Interdisciplinary Care of Children with Severe Bronchopulmonary Dysplasia.

Authors:  Steven H Abman; Joseph M Collaco; Edward G Shepherd; Martin Keszler; Milenka Cuevas-Guaman; Stephen E Welty; William E Truog; Sharon A McGrath-Morrow; Paul E Moore; Lawrence M Rhein; Haresh Kirpalani; Huayan Zhang; Linda L Gratny; Susan K Lynch; Jennifer Curtiss; Barbara S Stonestreet; Robin L McKinney; Kevin C Dysart; Jason Gien; Christopher D Baker; Pamela K Donohue; Eric Austin; Candice Fike; Leif D Nelin
Journal:  J Pediatr       Date:  2016-11-28       Impact factor: 4.406

Review 5.  Aerosolized diuretics for preterm infants with (or developing) chronic lung disease.

Authors:  L P Brion; R A Primhak; W Yong
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

Review 6.  Diuretics for transient tachypnoea of the newborn.

Authors:  Manal Kassab; Wadah M Khriesat; Jasim Anabrees
Journal:  Cochrane Database Syst Rev       Date:  2015-11-21

7.  Medication Repurposing in Pediatric Patients: Teaching Old Drugs New Tricks.

Authors:  Martha M Rumore
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

8.  Mice lacking NKCC1 are protected from development of bacteremia and hypothermic sepsis secondary to bacterial pneumonia.

Authors:  MyTrang Nguyen; Amy J Pace; Beverly H Koller
Journal:  J Exp Med       Date:  2007-05-21       Impact factor: 14.307

9.  Clinical pharmacology of furosemide in neonates: a review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2013-09-05

Review 10.  Phenotypes of Bronchopulmonary Dysplasia.

Authors:  Shih-Hsin Wang; Po-Nien Tsao
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.